2023
The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas
Moreira-Dinzey J, Zhan H, Rozenblit M, Krishnamurti U, Harigopal M, Zhong M, Liang Y. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas. Human Pathology 2023, 137: 56-62. PMID: 37127079, DOI: 10.1016/j.humpath.2023.04.017.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsEstrogen Receptor alphaFemaleHumansReceptors, EstrogenReceptors, ProgesteroneConceptsMetastatic tumorsBreast carcinomaGenetic aberrationsPR statusPrimary tumorBreast cancerControl groupER/PR statusEstrogen receptor-positive breast carcinomasER-positive breast cancerER positivity rateMetastatic breast cancerProgesterone receptor statusMetastatic breast carcinomaMore liver metastasesPrimary breast carcinomaWild-type groupEstrogen receptor 1 geneReceptor 1 geneWild-type controlsLiver metastasesReceptor statusClinicopathological featuresER expressionControl tumors
2022
Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities
Gohar J, Do W, Miller-Kleinhenz J, Conneely K, Krishnamurti U, D’Angelo O, Gogineni K, Torres M, Gabram-Mendola S, McCullough L. Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities. Breast Cancer Research And Treatment 2022, 191: 653-663. PMID: 34978015, DOI: 10.1007/s10549-021-06430-1.Peer-Reviewed Original ResearchConceptsNeighborhood-level factorsCause mortalityMultivariable Cox proportional hazards modelsCox proportional hazards modelCancer outcome disparitiesBreast cancer outcomesTumor methylationProportional hazards modelNon-Hispanic blacksArea-level factorsCancer outcomesFalse discovery rate thresholdBody of evidenceCancer disparitiesBreast cancerOutcome disparitiesCpG sitesTumor progressionTumor tissueWhite womenGuanine dinucleotide sitesRacial disparitiesMortalityTumor epigenomeLinear regression models
2020
HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
Zhao J, Krishnamurti U, Zhang C, Meisel J, Wei Z, Suo A, Aneja R, Li Z, Li X. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology - Research And Practice 2020, 216: 153155. PMID: 32871536, DOI: 10.1016/j.prp.2020.153155.Peer-Reviewed Original ResearchConceptsHigh HER2/CEP17 ratioHER2/CEP17 ratioTumor responseBreast cancer casesNeoadjuvant HER2CEP17 ratioNeoadjuvant chemotherapyIHC 3Breast cancerCancer casesRCB II/IIIHER2-positive breast cancerHER2 IHC 3Complete pathologic responseResidual cancer burdenSmaller tumor sizePositive breast cancerLow nuclear gradeHER2 copy numberHigh Ki67Pathologic responseCancer burdenExcisional specimensPositive cancersTumor sizeDetection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer
Maliniak M, Cheriyan A, Sherman M, Liu Y, Gogineni K, Liu J, He J, Krishnamurti U, Miller-Kleinhenz J, Ashiqueali R, He J, Yacoub R, McCullough L. Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer. Breast Cancer Research 2020, 22: 65. PMID: 32552729, PMCID: PMC7298873, DOI: 10.1186/s13058-020-01308-4.Peer-Reviewed Original ResearchConceptsBreast adipose tissueHazard ratioBreast cancerAdipose tissueMultivariable Cox proportional hazards modelsWhite womenCox proportional hazards modelProgression-free survivalMedical record reviewCurrent smoking statusConfidence intervalsProportional hazards modelBenign breast tissueBreast cancer prognosisNon-tumor tissuesCrown-like structuresMulti-racial populationEvidence of associationWorse OSWhite patientsClinical outcomesRecord reviewSmoking statusLifestyle factorsMultivariable modelObesity-associated methylation in breast tumors: a possible link to disparate outcomes?
Do W, Conneely K, Gabram-Mendola S, Krishnamurti U, D’Angelo O, Miller-Kleinhenz J, Gogineni K, Torres M, McCullough L. Obesity-associated methylation in breast tumors: a possible link to disparate outcomes? Breast Cancer Research And Treatment 2020, 181: 135-144. PMID: 32236829, DOI: 10.1007/s10549-020-05605-6.Peer-Reviewed Original ResearchConceptsCause mortalityER statusMultivariable Cox proportional hazards modelsCox proportional hazards modelBreast cancer tumor tissuesBreast cancer outcomesBreast cancer incidenceEstrogen receptor statusBody mass indexPrimary risk factorNon-Hispanic blacksCancer tumor tissuesReceptor statusMass indexCancer outcomesCpG sitesRisk factorsCancer incidenceBreast cancerHazards modelBreast tumorsTumor tissueWhite womenObesityRace disparities
2019
Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer
Meisel J, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer. Clinical Breast Cancer 2019, 20: 19-24. PMID: 31806448, DOI: 10.1016/j.clbc.2019.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreastBreast NeoplasmsCarcinoma, Ductal, BreastChemotherapy, AdjuvantDNA Copy Number VariationsDrug Resistance, NeoplasmFeasibility StudiesFemaleHumansLymphocytes, Tumor-InfiltratingMastectomyMiddle AgedNeoadjuvant TherapyPredictive Value of TestsProgression-Free SurvivalReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTumor BurdenConceptsTumor-infiltrating lymphocytesHER2-positive breast cancerNeoadjuvant therapyHER2/CEP17 ratioBreast cancerClinicopathologic featuresTumor sizeEstrogen receptorKi-67High HER2/CEP17 ratioCEP17 ratioHER2 immunohistochemistry 3Pathologic complete responseProgesterone receptor expressionSmaller tumor sizeBreast cancer responseHigh Ki-67Low estrogen receptorHER2 copy numberRCB-IIPatient ageClinicopathologic factorsComplete responseInitial biopsyExcisional specimensA whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk
Klimov S, Miligy I, Gertych A, Jiang Y, Toss M, Rida P, Ellis I, Green A, Krishnamurti U, Rakha E, Aneja R. A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. Breast Cancer Research 2019, 21: 83. PMID: 31358020, PMCID: PMC6664779, DOI: 10.1186/s13058-019-1165-5.Peer-Reviewed Original ResearchConceptsDCIS patientsRecurrence riskDuctal carcinomaScreen-detected breast cancerLong-term outcome dataBreast-conserving surgeryUnmet clinical needNottingham University HospitalsPositive predictive valueAdjuvant radiationIpsilateral recurrenceAdditional therapyMethodsThe cohortHazard ratioLocal recurrenceClinicopathological markersClinicopathological variablesPrimary tumorUniversity HospitalLymphocyte regionBreast cancerOutcome dataBenign ductsPredictive valuePatients
2017
GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma
Bivin W, Yergiyev O, Bunker M, Silverman J, Krishnamurti U. GRB7 Expression and Correlation With HER2 Amplification in Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2017, 25: 553-558. PMID: 26945445, DOI: 10.1097/pai.0000000000000349.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaHER2 amplificationHER2 overexpressionER negativityPathologic stageHistologic gradeP53 positivityGRB7 expressionBreast cancerBreast carcinomaInvasive breast cancer correlatesInvasive breast cancerBreast cancer correlatesChromosome 17 copy numberAntiestrogen therapyPR expressionPredictive factorsHER2 expressionCancer correlatesPR testingP53 immunohistochemistryAggressive phenotypeHER2 geneHER2P53 statusHormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients
Li X, Yang J, Krishnamurti U, Huo L, Ward K, O'Regan R, Peng L. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients. Clinical Breast Cancer 2017, 17: 356-366. PMID: 28576631, DOI: 10.1016/j.clbc.2017.03.005.Peer-Reviewed Original ResearchConceptsMale breast carcinomaFemale breast carcinomaHormone receptorsMBC patientsWorse OSOverall survivalBreast carcinomaBreast cancerStage IHormone receptor-positive breast cancerEarly-stage hormone receptorReceptor-positive breast cancerNational Cancer Institute's SurveillanceEnd Results (SEER) databaseWorse overall survivalBreast carcinoma casesSimilar survival ratesMBC subtypesWorse survivalClinicopathologic featuresOverall incidenceResults databaseWorse prognosisHER2 statusFBC patientsNew Developments in Breast Cancer and Their Impact on Daily Practice in Pathology
Li X, Oprea-Ilies G, Krishnamurti U. New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. Archives Of Pathology & Laboratory Medicine 2017, 141: 490-498. PMID: 28353377, DOI: 10.5858/arpa.2016-0288-sa.Peer-Reviewed Original ResearchConceptsBreast cancerDaily practiceBreast specimensTriple-negative breast cancerDistinct biological subsetsHER2/neu gene amplificationTumor-infiltrating lymphocytesRadioactive seed localizationAppropriate treatment groupsNovel clinical practicesNeu gene amplificationNeoadjuvant treatmentPathologic evaluationHistopathologic parametersTreatment groupsClinical practiceTherapeutic utilityBiological subsetsCancerMolecular classificationBest treatmentPathologyNew guidelinesSeed localizationGene amplificationTumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers
Krishnamurti U, Wetherilt C, Yang J, Peng L, Li X. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers. Human Pathology 2017, 64: 7-12. PMID: 28153508, DOI: 10.1016/j.humpath.2017.01.004.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsyBreast NeoplasmsChemotherapy, AdjuvantDisease ProgressionDisease-Free SurvivalFemaleHumansLogistic ModelsLymphatic MetastasisLymphocytes, Tumor-InfiltratingMastectomyMultivariate AnalysisNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPredictive Value of TestsProportional Hazards ModelsReceptors, EstrogenRisk FactorsTime FactorsTreatment OutcomeTriple Negative Breast NeoplasmsConceptsTriple-negative breast cancerTumor-infiltrating lymphocytesDisease-free survivalBetter overall survivalLymph node statusOverall survivalBreast cancerNeoadjuvant treatmentLymphovascular invasionEstrogen receptor-positive breast cancerReceptor-positive breast cancerOncotype DX recurrence scoreOncotype DX scorePossible prognostic valueDX recurrence scoreNottingham histologic gradeNeoadjuvant settingTILs correlateNegative associationNode statusPrognostic valueRecurrence scoreHistologic gradePrognostic parametersPathological responseDistinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations
Wright N, Xia J, Cantuaria G, Klimov S, Jones M, Neema P, Il’yasova D, Krishnamurti U, Li X, Reid M, Gupta M, Rida P, Osan R, Aneja R. Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations. PLOS ONE 2017, 12: e0170095. PMID: 28085947, PMCID: PMC5234824, DOI: 10.1371/journal.pone.0170095.Peer-Reviewed Original ResearchConceptsAdjuvant therapyNeoadjuvant chemotherapyRecurrence rateTumor recurrenceClinical studiesBreast cancer recurrence ratesBreast tumor recurrenceCohort of patientsBreast cancer patientsRate of recurrenceCancer recurrence rateAfrican American patientsFirst clinical studyHigh incidence rateEuropean American patientsForm of treatmentLocal recurrenceClinical outcomesPost therapyCancer patientsInvasive diseaseIncidence rateHigher overall rateRecurrence patternsHigh riskTargeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity.
Wright N, Rida P, Krishnamurti U, Li X, Aneja R. Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity. Frontiers In Bioscience-Landmark 2017, 22: 193-211. PMID: 27814611, DOI: 10.2741/4481.Peer-Reviewed Original ResearchConceptsEthnic disparitiesAfrican AmericansAggressive breast cancer subtypeUnique tumor biologyBreast cancer subtypesPrecision medicine toolsDiagnostic assaysIndividualized cancer treatmentRacial health disparitiesClinical outcomesDevelopment of drugsPatient populationAncestry-associated differencesEfficacy biomarkersTargeted drugsHigh recurrenceMortality rateCentrosomal aberrationsBreast tumorsTumor biologyCancer subtypesHealth disparitiesMedicine toolsCancer treatmentPersonalized oncology
2016
Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Li X, Krishnamurti U, Bhattarai S, Klimov S, Reid M, O’Regan R, Aneja R. Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. American Journal Of Clinical Pathology 2016, 145: 871-878. PMID: 27298399, DOI: 10.1093/ajcp/aqw045.Peer-Reviewed Original ResearchConceptsPathologic complete responseNeoadjuvant chemotherapyEstrogen receptorComplete responseLuminal subtypeProgesterone receptorBreast cancerTriple-negative breast cancer subtypeNottingham grade 3Stromal lymphocytic infiltrationNegative breast cancer subtypeBreast cancer patientsBreast cancer subtypesHigh mitotic countPR negativityHER2 positivityOverall cohortLymphocytic infiltrationTNBC subtypesCancer patientsHER2 statusPathologic parametersKi67 indexNuclear gradeClinical data
2015
GATA3 Immunohistochemistry Expression in Histologic Subtypes of Primary Breast Carcinoma and Metastatic Breast Carcinoma Cytology
Deftereos G, Ramirez A, Silverman J, Krishnamurti U. GATA3 Immunohistochemistry Expression in Histologic Subtypes of Primary Breast Carcinoma and Metastatic Breast Carcinoma Cytology. The American Journal Of Surgical Pathology 2015, 39: 1282-1289. PMID: 26274030, DOI: 10.1097/pas.0000000000000505.Peer-Reviewed Original ResearchConceptsTriple-negative breast carcinomaGCDFP-15Breast carcinomaCytology casesGynecologic malignanciesER expressionHistologic subtypeExpression correlatesMetastatic gynecologic malignanciesMetastatic breast carcinomaNegative breast carcinomaPrimary breast carcinomaStaining scoresNegative carcinomasOvarian carcinomaImmunohistochemistry expressionHistology casesMammaglobinCarcinomaIntensity scoresGATA3 expressionSubtypesGATA3Cancer cellsBreast
2014
HER2 in Breast Cancer
Krishnamurti U, Silverman J. HER2 in Breast Cancer. Advances In Anatomic Pathology 2014, 21: 100-107. PMID: 24508693, DOI: 10.1097/pap.0000000000000015.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsDrug DesignFemaleGene AmplificationHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMolecular Diagnostic TechniquesMolecular Targeted TherapyPrecision MedicinePredictive Value of TestsProtein Kinase InhibitorsReceptor, ErbB-2Signal TransductionTreatment OutcomeUp-RegulationConceptsBreast cancerHER2 receptorTime of diagnosisInvasive breast cancerHER2 receptor overexpressionValuable therapeutic targetHER2 biologyASCO guidelinesHER2 statusHER2 amplificationHER2 testingHER2 oncogeneTherapeutic targetReceptor overexpressionHER2CancerMembrane tyrosine kinaseTumor developmentCell proliferationCurrent standardReceptorsTyrosine kinaseChromosome 17q12RecurrenceTherapy
2011
Correlation of Immunohistochemical Expression of p53 With Unamplified Chromosome 17 Polysomy in Invasive Breast Carcinoma
Krishnamurti U, Zarineh A, Atem F, Silverman J. Correlation of Immunohistochemical Expression of p53 With Unamplified Chromosome 17 Polysomy in Invasive Breast Carcinoma. Applied Immunohistochemistry & Molecular Morphology 2011, 19: 28-32. PMID: 20823770, DOI: 10.1097/pai.0b013e3181e9bb6f.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaChromosome 17 polysomyBreast carcinomaHER2 amplificationReceptor negativityPrognostic indicatorNottingham scoreBreast cancerNeck squamous cell carcinomaNonsmall cell lung carcinomaHormone receptor negativityAdverse prognostic indicatorEstrogen receptor negativitySquamous cell carcinomaIndependent prognostic indicatorCell lung carcinomaCell carcinomaP53 positivityBladder carcinomaP53 immunostainingP53 overexpressionImmunohistochemical expressionLung carcinomaCarcinomaP53 expression
2009
Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma
Krishnamurti U, Hammers J, Atem F, Storto P, Silverman J. Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Modern Pathology 2009, 22: 1044-1048. PMID: 19396150, DOI: 10.1038/modpathol.2009.61.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaChromosome 17 polysomyBreast carcinomaHER2 gene amplificationBreast cancerChromosome 17 aneusomyHuman epidermal growth factor receptor 2 (HER2) oncoproteinAdverse prognostic factorAdverse prognostic indicatorEstrogen receptor negativityTreatment of patientsHigh nuclear gradePoor prognostic significanceGene amplificationPaucity of literatureReceptor negativityMost patientsPathologic factorsPrognostic factorsPredictive factorsPrognostic significanceHistologic gradePrognostic indicatorTumor stageHER2 overexpression